These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35626399)

  • 1. Multi Cancer Early Detection by Using Circulating Tumor DNA-The Galleri Test. Reply to Klein et al. The Promise of Multicancer Early Detection. Comment on "Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm.
    Pons-Belda OD; Fernandez-Uriarte A; Diamandis EP
    Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm.
    Klein EA; Beer TM; Seiden M
    Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can a Broad Molecular Screen Based on Circulating Tumor DNA Aid in Early Cancer Detection?
    Fiala C; Diamandis EP
    J Appl Lab Med; 2020 Nov; 5(6):1372-1377. PubMed ID: 33057613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm.
    Pons-Belda OD; Fernandez-Uriarte A; Diamandis EP
    Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-cause mortality as the primary endpoint for the GRAIL/National Health Service England multi-cancer screening trial.
    Carr D; Kent DM; Welch HG
    J Med Screen; 2022 Mar; 29(1):3-6. PubMed ID: 34847750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel blood-based early cancer detection: diagnostics in development.
    Beer TM
    Am J Manag Care; 2020 Nov; 26(14 Suppl):S292-S299. PubMed ID: 33200893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?
    Duffy MJ; Diamandis EP; Crown J
    Clin Chem Lab Med; 2021 Jul; 59(8):1353-1361. PubMed ID: 33856748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA as an early cancer detection tool.
    Campos-Carrillo A; Weitzel JN; Sahoo P; Rockne R; Mokhnatkin JV; Murtaza M; Gray SW; Goetz L; Goel A; Schork N; Slavin TP
    Pharmacol Ther; 2020 Mar; 207():107458. PubMed ID: 31863816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection.
    Fiala C; Diamandis EP
    BMC Med; 2018 Oct; 16(1):166. PubMed ID: 30285732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
    Fiala C; Diamandis EP
    Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can circulating tumor DNA be used for direct and early stage cancer detection?
    Diamandis EP; Fiala C
    F1000Res; 2017; 6():2129. PubMed ID: 29333251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of circulating copy number variant detection for cancer screening.
    Molparia B; Nichani E; Torkamani A
    PLoS One; 2017; 12(7):e0180647. PubMed ID: 28686671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
    Bremnes RM; Sirera R; Camps C
    Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA for Early Cancer Detection.
    Fiala C; Kulasingam V; Diamandis EP
    J Appl Lab Med; 2018 Sep; 3(2):300-313. PubMed ID: 33636948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer.
    Yin JX; Hu WW; Gu H; Fang JM
    J Cancer; 2021; 12(4):1258-1269. PubMed ID: 33442424
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating Bacterial DNA: A New Paradigm for Cancer Diagnostics.
    Glyn T; Purcell R
    Front Med (Lausanne); 2022; 9():831096. PubMed ID: 35445046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
    Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
    Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.
    Chalfin HJ; Glavaris SA; Gorin MA; Kates MR; Fong MH; Dong L; Matoso A; Bivalacqua TJ; Johnson MH; Pienta KJ; Hahn NM; McConkey DJ
    Eur Urol Oncol; 2021 Apr; 4(2):310-314. PubMed ID: 31563523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker.
    Lam WKJ; Chan KCA; Lo YMD
    J Pathol; 2019 Apr; 247(5):641-649. PubMed ID: 30714167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.